Acrongenomics, Inc. Appoints Chief Technology Officer
In his new role, Dr. Topoglidis will be responsible for providing Acrongenomics' management team with a solid scientific and technical vision. This includes understanding and translating Acrongenomics' science and technology-based capabilities into competitive advantages, implementing a compelling R&D pipeline and collaborating with government, academia and industry leaders in the life sciences industry. Dr. Topoglidis will also play a significant role in leading the Company's research team to define and assess viable opportunities for Acrongenomics, with particular interest in the realm of biosensors.
“Dr. Topoglidis' unique and in-depth background in the fields of nanotechnology and biology made him the ideal candidate to direct our technological vision. He provides invaluable experience relating to the intricacies of our current nanotechnology projects and will also set the tone in determining Acrongenomics' future biotechnology solutions.”
Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications which have been cited worldwide.
"In this new, ever-changing field of nanobiotechnology, it is paramount for our team to stay on top of the pioneering technologies, trends and unmet needs in the medical community," states Constantine Poulios, President of Acrongenomics. "Dr. Topoglidis' unique and in-depth background in the fields of nanotechnology and biology made him the ideal candidate to direct our technological vision. He provides invaluable experience relating to the intricacies of our current nanotechnology projects and will also set the tone in determining Acrongenomics' future biotechnology solutions."
Acrongenomics also announces new headquarters in Geneva, Switzerland to accommodate its forthcoming expansion phase, grow its collaborative network and centrally position itself in a first-rate European market. In addition to its rank as the leading financial center of Europe, Switzerland is a global leader in scientific and life sciences research, making it an excellent location. With a bustling biotechnology sector, Switzerland exhibits a solid cluster of world-class Universities, pharmaceutical giants, burgeoning biotech companies, key government organizations and industry associations. Acrongenomics is thrilled to explore the opportunities offered by the dynamic European economy.
About Acrongenomics, Inc.
Acrongenomics is a research-based investment firm that bridges the gap between breakthrough technologies and commercial development in the Life Sciences sector.